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Summary. In search of new inhibitors of the Ser/Thr protein kinase PknB from 
Mycobacterium tuberculosis we carried out a structure-based virtual screening study to 
identify ATP-competitive inhibitors of this enzyme. These studies resulted in the 
identification of N-phenylmethylindole-2-carboxamide as a promising scaffold for the 
development of new PknB inhibitors. We synthesized a small set of compounds to assess 
the pharmacophore structural requirements and to optimize the inhibitory activity against 
PknB. This strategy led to the identification of compound 3, endowed with an IC50 of 20 M, 
which provides a novel scaffold for further improvement of PknB inhibitors.  
 
 
 
 
Introduction 
Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis (TB), a major 
infectious disease that affects millions of people every year. As a bacterial pathogen, Mtb 
is the second leading cause of death, after the human immuno- deficiency virus [1]. The 
rapid emergence of first- and second-line drug resistant Mtb strains highlights the urgent 
need for new drugs to treat TB. 
 Mtb has a complex and dynamic life cycle including replicative and dormant states, 
highlighting that Mtb bacilli possess efficient signaling systems to sense the surroundings 
and adapt the physiology accordingly. Mtb codes for eleven eukaryotic-like Ser/Thr Protein 
Kinases (STPKs) [2]. Among these, the trans-membrane (receptor-like) STPK PknB is the 
only Mtb kinase that is upregulated during the exponential growth phase [3-5] upon 
macrophage infection [6] and repressed under nutrient starvation in a model of persistent 
Mtb [7]. Furthermore, PknB has been shown to be essential for Mtb growth [8] being 
required to phosphorylate substrates involved in cell-wall biogenesis [9]. Therefore, PknB 
has been established as a valid target for the design of new anti TB drugs [10-12]. 
 The PknB kinase domain adopts the typical two-lobed structure found in STPKs. The 
kinase N-lobe encompasses several β-sheets and a regulatory α-C helix, while the C-
terminal lobe is mainly helical. The ATP-binding and protein substrate-binding sites reside 
at the interface between these two sub-domains [13,14]. 
 
 
          
 
 
 
 
 
 
 
Figure 1. Binding mode of 1 (magenta) (panel A) and 2 (gray) (panel A) proposed by Plants. 
Residues involved in interactions are highlighted as lines, hinge region residues are reported as 
stick (cyan), the PknB ATP binding site is shown as a cartoon (yellow) and H-bonds are depicted 
as dotted lines (black).   
 
 
 
 
          
 
 
 
 
Results and discussion 
Virtual screening study 
We carried out a structure-based virtual screening (VS) study using an in-house library of 
5000 compounds, all following Lipinski’s rules [15], and the crystal structure of PknB 
obtained in presence of the competitive inhibitor mitoxantrone (PDB code: 2FUM) [16]. 
The whole compound library was docked into the PknB ATP binding site using Plants [17] 
and Autodock [18]. To assess the ability of the docking protocol to discriminate active vs 
inactive compounds, we separately analysed a test set comprising the co-crystallized 
mitoxantrone and other PknB inhibitors previously studied [12]. Both Plants and Autodock 
provided consistent binding modes for all compounds, but the correlation between docking 
score and in vitro inhibitory activity was unsatisfactory. Hence, we decided to select only 
those compounds having a RMSD <2, between the best energy poses obtained by Plants 
and Autodock [19]. This selection filtered the library including over 1000 compounds, 
which were then ranked by number of H-bonds formed with the hinge region of PknB [20]. 
The best 100 molecules were visually inspected and the most promising molecules were 
experimentally analysed to assess their in vitro inhibitory activity against PknB. 
Compounds 1 and 2 were newly synthesized and evaluated as PknB inhibitors. These 
compounds inhibited 50% of PknB kinase activity at the concentration of 100 M (Table 1). 
 Compound 1 was predicted to bind the ATP pocket of PknB by establishing two H-
bonds with residues Glu93 and Val95 in the kinase hinge region, which acts in the 
positioning of the ATP substrate. The bis-indole moiety is stabilized by hydrophobic 
interactions with the side chains of residues Leu17 (at the N-terminus of the kinase glycine 
rich loop), Met45, Ala142 and Met145 (deep in the ATP binding pocket). An additional key 
H-bond engages residue Lys140, located in the catalytic loop of PknG, right after the HRD 
motif (Figure 1A). 
 Compound 2 also binds the ATP pocket of PknB by forming H-bonds with the kinase 
hinge region. While the compound indole ring establishes hydrophobic interactions with 
residues Leu17 and Met145, the benzyl ring interacts with the side chains of Val25 and 
Val72. Also, the aromatic amino group establishes two H-bonds, one with the conserved 
residue Glu59 (involved in the locked-in positioning of the regulatory C helix through a 
salt bridge with the catalytic Lys40), and other with residue Asp176 in the DFG motif 
(Figure 1B). 
 
          
 
 
 
 
Table 1. Structure and PknB Inhibition by Compounds 1-9a) 
 
Compound R1 R2 R3 PknB % inhibitionb) 
1 - - - 50 
2 Cl H 4-NH2 50 
3 Cl Phenyl 3-NH2 83 
4 Cl H 3-Cl 42 
5 Cl H 3-NH2 20 
6 Br H 3-NH2 20 
7 Cl H 4-NO2 56 
8 Cl H 2-NH2 39 
9 Cl H 2-NO2 53 
a)
 Data are mean values of two to three independent experiments 
performed in duplicate. Standard deviations correspond to 10% of 
the measured value in each case. 
b)
 PknB % of inhibition; PknB was 30 nM, GarA was 20 M and 
compound was 100 M. 
 
 
 While compounds 1 and 2 were determined to be equipotent as PknB inhibitors, 2 was 
selected for further optimization because of its better drug-like properties predicted by 
QikProp software [21]. Descriptors computed for compound 2 were always better than that 
of compound 1 (Table 1S Supporting Information). Indeed no deviation from Lipinski’s rule 
was accounted. 
 Molecular dynamics (MD) simulations of the PknB-2 complex confirmed the H-bonds 
between the compound and the residues within the kinase hinge region, with a calculated 
rate of formation <80%. The hydrophobic contacts remained stable along the trajectory, 
while the H-bonds involving the compound aromatic amino group disappeared quickly. No 
significant movements of the complex were observed, suggesting the stabilization of the 
two kinase lobes upon ligand binding (Figure 1S, Supporting Information). 
 An in-silico library of compound 2 analogues was generated by superimposition of its 
binding mode with those of compounds within the test set. Compounds 3-9 (Table 1), 
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which were predicted as the most efficient PknB inhibitors by docking simulations, were 
synthesized and analyzed in vitro. 
 It is well known that many kinase inhibitors are not selective because they 
interact with the ATP binding region that has similar geometry amongst the protein 
kinases. With the aim of assessing the compounds selectivity we firstly identified the 
kinases (available at protein data bank [22]) with the highest PknB similarity score, using 
CPASS [23, 24]. We then docked compounds 2-9 with the proteins identified in the 
previous step. CPASS identified three other kinases as the most similar to PknB: MAP1 
(64.1%), GSK-3 3% and Aurora-A (60.8%). Compounds 2-9 binding poses for 
MAP1 and GSK-3 observed for PknB, while a 
different binding mode was observed for Aurora-A. From these results we could speculate 
that the compounds reported might not be very selective toward PknB, following the 
definition of kinase type I inhibitors [25]. 
 
 
Chemistry 
Synthesis of 1 was carried out by a Pd-mediated cross-coupling reaction 13 and 24 
(Scheme 1). Carboxamides 4, 17 and 18 were synthesized by coupling the indole-2-
carboxylic acid 14-16 with the corresponding amine in the presence of BOP reagent and 
triethylamine (TEA) in anhydrous DMF at 25 °C for 12 h (Scheme 2). Alternatively, an 
appropriate carboxylic acid was activated by treatment with 1,1’-carbonyldiimidazole in 
anhydrous THF, then treated with the amine to produce compounds 9 or 19. Compound 7 
was obtained by reaction of 15 with 4-nitrobenzylamine hydrochloride in the presence of 
PyBOP reagent and TEA in anhydrous DMF at 25 °C for 12 h. Tin(II) chloride reduction of 
the nitro derivatives 7, 9 and 17-19 in ethyl acetate at 80 °C for 3 h furnished compounds 2, 
3, 5, 6 and 8, respectively. Pinacol ester 13 was synthesized starting from 10 that, after 
reaction with pivaloyl chloride in the presence of TEA in anhydrous THF at 25 °C for 12 h, 
was iodinated at position 2 by using the Katritzky method [26] and then transformed into 
the corresponding boronic ester according to Miyaura reaction conditions [27] under 
microwave (MW) irradiation (Scheme 1). Reaction of 20 with chloroacetonitrile in the 
presence of NaH in anhydrous DMF at 25 °C for 12 h furnished derivative 21, that after 
reduction with LiAlH4 in anhydrous THF at 50 °C for 4 h and subsequent treatment with 
pivaloyl chloride, as above described, was transformed into 22 (Scheme 3). Compound 22 
          
 
 
 
 
was treated with oxalyl chloride in anhydrous diethyl ether for 3 h and then with methanol 
in the presence of TEA for 5 h to furnish the methyl 2-oxoacetate 23, that was converted 
into the corresponding amide 24 by treatment with 28% NH4OH in ethanol at 130 °C (150 
W) for 15 min. Carboxylic acid 14 was obtained by bromination of ester 25 with N-
bromosuccinimide (NBS) to give the corresponding 3-bromo derivative 26 (Scheme 4). 
Treatment of 26 with phenylboronic acid in the presence of Pd(dppf)Cl2·CH2Cl2 and 
Na2CO3 in 1,4-dioxane at 100 °C for 16 h provided the 3-phenylindole 27 (Scheme 4). 
Compound 27 was transformed into the corresponding carboxylic acid 14 by hydrolysis 
with LiOH·H2O in aqueous THF at 25 °C for 12 h. 
 
 
 
 
 
Scheme 1. Chemical synthesis of compound 1. Reagents and 
conditions: (a) pivaloyl chloride, TEA, anhydrous THF, 25 °C, 
12 h, 82%; (b) (i) n-BuLi, -78 °C, anhydrous THF, Ar stream, 30 
min; (ii) CO2g, 10 min; (iii) tert-BuLi, -78 °C, anhydrous THF, Ar 
stream, 1 h; (iv) 1,2-diiodoethane, -78 °C, 1 h, Ar stream, 25%; 
(c) pinacol borane, TEA, SPhos, PdCl2(CH3CN)2, toluene, 
closed vessel, 250 W, 20 min, PowerMAX, 97%; (d) 24, K3PO4, 
DMF, Pd(dppf)Cl2·CH2Cl2, 60 °C, 1 h, Ar stream, 85%. 
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Scheme 2. Chemical synthesis of compounds 2-9 (Table 1); 
14: R1 = Cl, R2 = Ph; 15: R1 = Cl, R2 = H; 16: R1 = Br, R2 = H; 
17: R1 = Cl, R2 = H, R3 = 3-NO2; 18: R1 = Br, R2 = H, R3 = 3-
NO2; 19: R1 = Cl, R2 = Ph, R3 = 3-NO2. Reagents and 
conditions: (a) (4, 10, 11) amine, BOP reagent, TEA, anhydrous 
DMF, 25 °C, 12 h, 47-81%; (b) (9, 12) (i) 1,1'-
carbonyldiimidazole, anhydrous THF, 25 °C, 2 h; (ii) amine, 
25 °C, 2 h, 42-59%; (c) (7) amine, PyBOP reagent, TEA, 
anhydrous DMF, 25 °C, 12 h, 30%; (d) SnCl2∙2HO, AcOEt, 
80 °C, 3 h, 54-87% . 
 
 
 
 
 
 
 
Scheme 3. Chemical synthesis of compound 24. Reagents and 
conditions: (a) (i) NaH, anhydrous DMF, 25 °C, 30 min; (ii) 
chloroacetonitrile, 25 °C, 12 h, 40%; (b) LiAlH4, anhydrous THF, 
50 °C, 4 h, crude product; (c) pivaloyl chloride, TEA, anhydrous 
THF, 50 °C, 12 h, 10%; (d) (i) oxalyl chloride, anhydrous Et2O, 
0 °C for 1.5 h then 25 °C for 1.5 h, Ar stream; (ii) MeOH, TEA, 
0 °C for 1 h then 25 °C for 4 h, 25%; (e) 28% NH4OH, EtOH, 
closed vessel, 150 W, 130 °C, 15 min, 73%. 
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Scheme 4. Chemical synthesis of compound 14. Reagents and 
conditions: (a) NBS, anhydrous DMF, 80 °C, 3 h, 37%; (b) 
phenylboronic acid, Pd(dppf)Cl2·CH2Cl2, Na2CO3, 1,4-dioxane, 
100 °C, 16 h, 70%; (c) LiOH·H2O, THF/H2O, 25 °C, 12 h, 96%. 
 
 
 
Biological activity 
Among the group of compounds 3-9, bearing the N-benzyl at the indole-2-carboxamide, 
derivative 3 inhibited PknB activity by 83% at a concentration of 100 M and showed an 
IC50 value of 20 M. There was no evident major difference among the substituents at the 
N-benzyl moiety of 4-9. These compounds inhibited PknB in the 39-56% range, although 
the data are limited. Docking analyses of 3 showed the 3-phenyl ring filled a hydrophobic 
pocket comprising residues Leu17 and Met155, thus ensuring a better stabilization of the 
complex within PknB active site (Figure 2). MD simulations of the complex PknB-3 
highlighted a rate of formation near to 100% for the H-bonds within the kinase hinge region, 
evidencing an improvement over compound 2. The 3-phenylindole group established 
contacts with PknB residues Met145, Met155 and Leu17. The benzyl ring was stabilized 
by hydrophobic contacts with Val25, no H-bond interactions were observed for the 3-amino 
group. 
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Figure  2. Snapshot of compound 3 (cyan) trajectory. Residues involved in interactions are depicted as 
sticks (magenta), the PknB binding site is shown as a cartoon and H-bonds are depicted as dotted lines 
(black). 
 
 
 
Conclusion 
A structure-based VS using the ATP binding site of the Ser/Thr protein kinase PknB was a 
powerful technique for the discovery of novel scaffolds 1 and 2 with PknB inhibitory activity. 
Additional in silico studies led to design and synthesize a small compound library of 
compounds 3-9. Compound 3 showed promising inhibition with activity an IC50 value 
against PknB of 20 M. Current investigations are progress in our research group to clarify 
the structural requirements for further development of this novel class of potential anti-Mtb 
compounds. 
 
  
          
 
 
 
 
 
Experimental 
Chemistry 
N-(3'-(2-Amino-2-oxoacetyl)-1'-(2-pivalamidoethyl)-1H,1'H-[2,5'-bi-indol]-6-yl)pivalamide (1). 
A mixture of 13 (0.34 g, 0.99 mmol), 24 (0.30 g, 7.6 mmol) and K3PO4 (0.48 g, 2.3 mmol) 
in DMF was degassed for 15 min. Pd(dppf)Cl2·CH2Cl2 (0.019 g, 0.023 mmol) was added 
and the reaction mixture was heated at 60 °C for 1 h under Ar stream, cooled and diluted 
with water. The organic layer was extracted with ethyl acetate, washed with brine, dried 
and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:ethanol = 95:5 as eluent) to furnish 1 (0.34 g, 
85%), mp 165-168 °C (from ethanol). 1H NMR (DMSO-d6):  0.96-1.00 (m, 9H), 1.22-1.26 
(m, 9H), 3.41-3.45 (m, 2H), 4.39-4.41 (m, 2H), 6.75-6.77 (m, 1H), 7.13-7.16 (m, 1H), 7.39-
7.80 (m, 4H; 2H after treatment with D2O), 7.92-7.94 (m, 1H), 8.05 (br s, disappeared on 
treatment with D2O, 1H), 8.34-8.36 (m, 1H), 8.67-8.70 (m, 2H), 9.07-9.09 (m, disappeared 
on treatment with D2O, 1H), 11.52 ppm (br s, disappeared on treatment with D2O, 1H). IR:  1625, 2961, 3318 cm-1. Anal. calcd for C30H35N5O4 (529.64); calcd %: C 68.03, H 6.66, N 
13.22, found %: C 68.00, H 6.61, N 13.20. 
 
General procedure for the synthesis of compounds 2, 3, 5, 6 and 8. Example. N-(4-
Aminobenzyl)-5-chloro-1H-indole-2-carboxamide (2). 
SnCl2∙2H2O (0.203 g, 0.9 mmol) was added to a solution of 7 (0.10 g, 0.3 mmol) in ethyl 
acetate (18.0 mL). The reaction was heated at reflux at 80 °C for 3 h. After cooling, the 
reaction mixture was made basic with a saturated aqueous solution of NaHCO3 and 
filtered. The organic layer was washed with brine, dried and filtered. Removal of the 
solvent gave a residue that was purified by column chromatography (silica gel, n-
hexane:ethyl acetate = 2:3 as eluent) to provide 2 (0.06 g, 66%), mp 236-240 °C (from 
ethanol). 1H NMR (DMSO-d6):  4.30-4.31 (d, J = 4.8 Hz, 2H), 4.96 (br s, disappeared on 
treatment with D2O, 2H), 6.50-6.52 (d, J = 7.6 Hz, 2H), 6.97-6.99 (d, J = 8.0 Hz, 2H), 7.12 
(s, 1H), 7.15-7.17 (d, J = 8.0 Hz, 1H), 7.40-7.42 (d, J = 8.4, 1H), 7.67 (s, 1H) , 8.91 (br s, 
disappeared on treatment with D2O, 1H), 11.77 ppm (br s, disappeared on treatment with 
D2O, 1H). IR:  1640, 3219, 3408, cm-1. Anal. calcd for C16H14ClN3O (299.76); calcd %: C 
64.11, H 4.71, N 14.02, Cl 11.83, found %: C 63.88, H 4.65, N 13.78, Cl 11.55. 
 
          
 
 
 
 
N-(3-Aminobenzyl)-5-chloro-3-phenyl-1H-indole-2-carboxamide (3). 
Was synthesized as 2 starting from 19. Yield 54%, mp 145-150 *C (from ethanol). 1H NMR 
(DMSO-d6):  4.23-4.24 (d, J = 5.8 Hz, 2H), 5.00 (br s, disappeared on treatment with D2O, 
2H), 6.31-6.33 (d, J = 7.16 Hz, 1H), 6.40-6.42 (m, 2H), 6.89-6.93 (t, J = 8.2 Hz, 1H), 7.22-
7.26 (m, 1H), 7.32-7.36 (m, 1H), 7.42-7.49 (m, 6H), 7.80-7.82 (t, J = 6.1 Hz, disappeared 
on treatment with D2O, 1H), 11.96 ppm (br s, disappeared on treatment with D2O, 1H). IR:  1649, 3130, 3408 cm-1. Anal. calcd for C22H18ClN3O (375.86); calcd %: C 70.30, H 4.83, 
N 11.18, Cl 9.43, found %: C 70.12, H 4.78, N 10.95, Cl 9.22. 
 
Biological assays 
PknB inhibition assay 
 PknB inhibition assays were carried out in a final volume of 20 L, containing 50 mM 
HEPES, pH 7.0, 1 mM DTT, 1 mM MnCl2 and 20 M GarA as a substrate. Compounds 
(100 M in each case) were initially incubated for 30 min at 4 °C with the reaction mixture 
containing 30 nM PknB. Then, kinase reactions were started by adding 100 M ATP (1 Ci 
-
33P] ATP) and were carried out for 30 min at 37 °C. Reactions were stopped by heat 
L were spotted onto 
P81 paper (phosphocellulose, Whatman). The paper was washed with 1% v/v phosphoric 
acid, rinsed with acetone and allowed to dry. Radiolabelled spots were analyzed with a 
phosphoimager (Storm, Molecular Dynamics). Each reaction was performed in duplicates 
[28]. 
 
Molecular modelling 
 Hydrogen atoms were added to the crystal structure of PknB (PDB code: 2FUM) by 
using Molecular Operating Environment (MOE) 2007.09 [29] and minimized, keeping all 
the heavy atoms fixed until a rmsd gradient of 0.05 kcal mol-1 Å-1 was reached. Ligand 
structures were built with MOE and minimized using the MMFF94x force field until a rmsd 
gradient of 0.05 kcal mol-1 Å-1 was reached. Docking simulations were performed using 
PLANTS [17] and Autodock 4.0 [19]. We set up the binding lattice on a sphere of 15 Å 
radius for PLANTS and on a cubic lattice of 60 60 60 npts for Autodock, centered on the 
inhibitor mitroxantone. Default settings were used.  
Molecular dynamics were performed employing the AMBER 10 suite [30, 31] The 
minimized structure was solvated in a periodic octahedron simulation box, using TIP3P 
          
 
 
 
 
water molecules, providing a minimum of 10 Å of water between the protein surface and 
any periodic box edge. Ions were added to neutralize the charge of the total system. The 
water molecules and Na+ ions were energy-minimized, keeping the coordinates of the 
protein-ligand complex fixed (1,000 cycles), and then the whole system was minimized 
(5,000 cycles). Next, the entire system was heated and thermalized to 298 K (5 ps). The 
simulation was conducted at 298 K, with constant pressure and periodic boundary 
condition. Shake bond length condition was used (ntc = 2). Compounds were 
parameterized by Antechamber [32, 33] using BCC charges. Trajectories analysis were 
carried our by ptraj program [34]. The images in the manuscript were created with PyMOL 
[35]. 
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Graphical abstract 
 
 
 
A structure-based virtual screening study into the ATP binding site of the Ser/Thr protein 
kinase PknB led to the discovery of compounds 1 and 2 as novel scaffolds endowed with 
PknB inhibition. A small compound library of compounds 3-9 was synthesized on the basis 
of the computational studies. N-(3-Aminobenzyl)-5-chloro-3-phenyl-1H-indole-2-
carboxamide (3) showed promising inhibition of PknB with an IC50 value of 20 M.  
 
 
